Aberrant activation of the PI3K/Akt/mTOR pathway has been reported in approximately 50% of hepatoma cases [10], thereby exerting significant influence on the various facets of hepatoma initiation as well as progression, including tumor cell proliferation, differentiation, metabolism, autophagy, and immune regulation [11,12]. This evidence concerns the gene MTOR and hepatocellular carcinoma.